Cohort Study of Patients With Hepatocellular Carcinoma and Circulating Tumor DNA Monitoring of Chemoembolization

NCT05390112 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 167

Last updated 2022-05-25

No results posted yet for this study

Summary

Cohort study to assess the impact of ctDNA detection in the follow-up and management of patients with hepatocellular carcinoma treated by TACE

Conditions

  • Circulating Tumor DNA
  • Hepatocellular Carcinoma Non-resectable
  • Transarterial Chemoembolization

Interventions

BIOLOGICAL

DNA

ctDNA; cfDNA

Sponsors & Collaborators

  • University Hospital, Rouen

    lead OTHER

Principal Investigators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-20
Primary Completion
2024-06-30
Completion
2024-12-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05390112 on ClinicalTrials.gov